Olr395 inhibitors are a class of chemical compounds that specifically target and modulate the activity of the Olr395 protein, which belongs to the olfactory receptor family. These receptors are part of the G protein-coupled receptor (GPCR) superfamily, characterized by their seven transmembrane domain structure. Olr395 is one of the many olfactory receptors involved in detecting specific molecules, primarily in the context of olfaction. However, the function of Olr395 may extend beyond smell perception, given the expanding recognition of olfactory receptors in various tissues outside the olfactory epithelium. The inhibition of Olr395 can lead to alterations in signaling pathways typically initiated by the binding of ligands to this receptor, which in turn can affect the downstream processes governed by these signals. The study of Olr395 inhibitors provides insight into the fundamental mechanisms by which olfactory receptors can influence cellular processes through their modulation.
These inhibitors are structurally diverse, often characterized by their ability to bind selectively to the Olr395 receptor, preventing its interaction with natural ligands. The specificity of these inhibitors is crucial, as it allows for the precise study of Olr395 function without affecting other olfactory receptors. Researchers typically employ a variety of in vitro and in vivo techniques to evaluate the binding affinity, selectivity, and potency of Olr395 inhibitors. Structural analysis, including crystallography and computational modeling, is frequently used to determine the binding sites and conformational changes induced by these inhibitors. Additionally, the synthesis of these compounds often involves complex chemical processes to optimize their stability and efficacy in experimental settings. The ongoing research into Olr395 inhibitors is pivotal in expanding our understanding of olfactory receptor functions and their broader implications in various biological systems.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Allopurinol | 315-30-0 | sc-207272 | 25 g | $128.00 | ||
Xanthine oxidase inhibitor, can indirectly affect GPCR signaling through purine metabolism, potentially impacting Olr395. | ||||||
Carvedilol | 72956-09-3 | sc-200157 sc-200157A sc-200157B sc-200157C sc-200157D | 100 mg 1 g 10 g 25 g 100 g | $122.00 $235.00 $520.00 $979.00 $1500.00 | 2 | |
Non-selective beta-adrenergic blocker, may influence GPCR signaling pathways, potentially affecting Olr395. | ||||||
Daclatasvir | 1009119-64-5 | sc-500663 | 100 mg | $330.00 | ||
HCV NS5A inhibitor, could indirectly affect GPCR signaling through viral replication inhibition, impacting Olr395. | ||||||
Erlotinib Hydrochloride | 183319-69-9 | sc-202154 sc-202154A | 10 mg 25 mg | $74.00 $119.00 | 33 | |
EGFR tyrosine kinase inhibitor, might modulate GPCR signaling indirectly through tyrosine kinase pathways, impacting Olr395. | ||||||
Furosemide | 54-31-9 | sc-203961 | 50 mg | $40.00 | ||
Loop diuretic, can alter GPCR signaling indirectly through its diuretic effect, potentially impacting Olr395. | ||||||
Indomethacin | 53-86-1 | sc-200503 sc-200503A | 1 g 5 g | $28.00 $37.00 | 18 | |
Non-steroidal anti-inflammatory drug, could influence GPCR signaling indirectly via prostaglandin synthesis inhibition, impacting Olr395. | ||||||
Losartan | 114798-26-4 | sc-353662 | 100 mg | $127.00 | 18 | |
Angiotensin II receptor antagonist, may modulate GPCR signaling pathways, potentially affecting Olr395. | ||||||
Metformin | 657-24-9 | sc-507370 | 10 mg | $77.00 | 2 | |
Biguanide antidiabetic, can affect GPCR signaling indirectly via AMPK activation and glucose regulation, impacting Olr395. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $205.00 $405.00 | 9 | |
Tyrosine kinase inhibitor, might influence GPCR signaling indirectly, potentially impacting Olr395. | ||||||
Propranolol | 525-66-6 | sc-507425 | 100 mg | $180.00 | ||
Beta-adrenergic blocker, could alter GPCR signaling, potentially impacting Olr395. | ||||||